SCHEDULE: Sofinnova Group Reports 4.1% Stake in ArriVent Biopharma

Sofinnova Venture Partners XI and its affiliates have filed an amended Schedule 13G, disclosing a 4.1% beneficial ownership in ArriVent Biopharma, Inc. as of December 31, 2025.

Summary

• Sofinnova Venture Partners XI, L.P. (SVP XI), along with Sofinnova Management XI, L.P. (SM XI LP), Sofinnova Management XI, L.L.C. (SM XI LLC), Dr. James I. Healy, and Dr. Maha Katabi, collectively referred to as the Reporting Persons, beneficially own 1,696,752 shares of ArriVent Biopharma, Inc. Common Stock.
• This beneficial ownership represents 4.1% of ArriVent Biopharma, Inc.'s outstanding Common Stock as of December 31, 2025.
• The filing is an Amendment No. 1 to a Schedule 13G, updating the beneficial ownership information previously filed on November 12, 2024.
• Dr. James I. Healy, a managing member of SM XI LLC, is also a director of ArriVent Biopharma, Inc.
• The Reporting Persons disclaim beneficial ownership of shares of Common Stock, except to the extent of their pecuniary interest therein or shares held of record.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine disclosure of beneficial ownership by a passive institutional investor, providing no new material information regarding the company's operational or financial performance.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding ArriVent Biopharma, Inc.'s future performance or strategic direction.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for passive institutional investors. Sofinnova's continued stake, even if below the 5% threshold, indicates ongoing interest in the biopharmaceutical sector and ArriVent Biopharma specifically. Such filings provide transparency on significant ownership positions within the industry.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for institutional investors reporting passive ownership stakes below 5%. Venture capital firms like Sofinnova frequently take such positions in emerging biopharma companies, aligning with typical investment strategies in the sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding the beneficial ownership structure of the company's common stock by a significant institutional investor group.

Key Dates

Recommendation

This filing is a routine disclosure of beneficial ownership by a passive institutional investor group. It does not contain new financial or operational information that would warrant a change in investment recommendation. The 4.1% stake is below the 5% threshold, indicating a non-activist position.

Keywords

ArriVent Biopharma, Sofinnova, Schedule 13G, beneficial ownership, common stock, institutional investor, venture capital, biopharma